Drug Profile

Belimumab - AstraZeneca/GSK

Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LSB; LymphoStat-B; monoclonal anti-BLyS

Latest Information Update: 30 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cambridge Antibody Technology; Human Genome Sciences
Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; GSK; Hospital for Special Surgery; Human Genome Sciences; National Institute of Allergy and Infectious Diseases; North Shore-Long Island Jewish Health System; University of Pennsylvania; University of Wisconsin-Madison; Washington University School of Medicine
Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
Mechanism of Action B cell activating factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Systemic lupus erythematosus
New Molecular Entity Yes

Marketed Lupus nephritis; Systemic lupus erythematosus
Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Interstitial lung diseases
Phase II/III Myositis; Systemic scleroderma
Phase II Membranous glomerulonephritis; Multiple sclerosis; Myasthenia gravis; Renal transplant rejection
No development reported Graft-versus-host disease; Waldenstrom's macroglobulinaemia
Discontinued Rheumatoid arthritis; Sjogren's syndrome

25 Jun 2025 Registered for Lupus nephritis (In children, In adolescents) in USA (SC)
12 Dec 2024 Phase-III clinical trials in Interstitial lung diseases in Argentina, South Korea (SC) (NCT06716606) (EudraCT2023-509370-39)
04 Dec 2024 GlaxoSmithKline plans a phase III trial for Interstitial lung diseases (systemic sclerosis associated interstitial lung disease) in Argentina, Belgium, Brazil, China, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, South Korea, Spain (SC, Injection) (NCT06716606)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com